The agreement will link Nevisense with SciBase's EIS measurement for early detection of malignant melanoma, with DermoScan's digital dermoscopy system DermoGenius Ultra.

Various clinics in Germany and other markets use DermoScan's systems .

Nevisense uses EIS which is based on the varying electrical properties of human tissue to categorise cellular structures and helps in detecting malignancies.

With this agreement, Nevisense’s Electrical Impedance Spectroscopy (EIS) measurements will be integrated as a standard option in DermoGenius Ultra.

From now on, both patient data and Nevisense’s EIS measurements can be shared between the two systems. It is expected that the integration will improve a clinic’s workflow along with the diagnostic process for dermatology clinics.

The two companies stated that the will conduct a joint marketing effort to promote the integrated solution. According to SciBase, the customer-base of DermoScan can provide it with the opportunity to reach key target groups.

SciBase CEO Simon Grant said: “The partnership with DermoScan is an opportunity for SciBase for two reasons – it gives us a channel to reach out to a larger audience and it means that we can provide a better, more integrated solution for clinicians.

“We see the inclusion of Nevisense EIS as a parameter in the DermoGenius system as a sign of the growing interest in Nevisense and our method.

“We believe that DermoScan's broad customer network will have a positive effect on the market penetration of Nevisense.”

DermoScan president Johann Tillmann said: “We are very happy to reach an agreement to cooperate with the team at SciBase. Nevisense is an exciting new technology that complements perfectly our digital dermatoscopy system DermoGenius Ultra.

“Integrating the products will help save time and improve patient flow for our customers. We are also looking forward to cooperating in the market with joint sales and marketing activities.”